The most important biomarker associated with coagulation and inflammation among COVID-19 patients

Area of Science:

• * Infectious Diseases
• * Hematology
• * Critical Care Medicine

Background:

• * Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is associated with coagulopathy and disseminated intravascular coagulopathy (DIC).
• * The global spread of COVID-19 presents challenges in managing its complications, including multi-organ failure.
• * Acute lung injury is a primary concern, but systemic effects like coagulopathy are significant.

Purpose of the Study:

• * To investigate the relationship between COVID-19 infection and coagulopathy.
• * To identify key biomarkers for early detection and management of COVID-19 complications.
• * To provide guidance on managing COVID-19-associated coagulopathy.

Main Methods:

• * Review of clinical presentations and laboratory findings in COVID-19 patients.
• * Analysis of coagulation parameters (D-dimer, fibrinogen, platelet count, PT&PTT).
• * Assessment of inflammatory biomarkers (CRP, LDH, IL-6, ferritin).

Main Results:

• * COVID-19 coagulopathy is characterized by elevated D-dimer, ferritin, and fibrinogen degradation products.
• * Early stages show significant elevations in inflammatory markers (CRP, LDH, IL-6).
• * Platelet count and clotting times (PT/PTT) may be less affected initially.

Conclusions:

• * Screening for inflammation and coagulation abnormalities is vital for detecting SARS-CoV-2 infection.
• * COVID-19-associated coagulopathy requires management similar to other critical conditions.
• * Supportive care and thromboembolic prophylaxis are recommended for severe COVID-19 patients.